Mostafavi said; “In 99% of those who received 3 doses of PastoCovac vaccine, the antibody increased up to 4 times.”
As reported by Radio Goftogoo, "Scientific Dialogue" program had an interview with Dr. Ehsan Mostafavi, an Iranian epidemiologist, faculty member and head of the Pasteur Institute for Emerging and Re-emerging Diseases Research Center, regarding the effectiveness of Iranian vaccines against new variants of the Corona virus.
Mostafavi explained; “Immunization and effectiveness are among the factors that are taken into consideration for the effectiveness of the vaccine.”
He emphasized that the effectiveness of the vaccine is especially important; “In the case of Iran and Cuba joint vaccine, we injected 24,000 volunteers, fake vaccines and vaccines, and in a certain period of time, we examined them and identified the effectiveness of this vaccine. For those who received 3 doses of the vaccine, we could see that it’s about 65% effective in the prevention of symptomatic forms and about 96% in the prevention of severe and inpatient forms, and therefore most of the approved vaccines are definitely effective and prevents of different variants.”
The Iranian epidemiologist then stressed that those who do not get vaccinated harm others; “In the case of the new variants, from the beginning, all companies were of the opinion that with viral mutations, changes should be made to the vaccine. The truth is the international community does not yet have thorough information about the Omicron variant, and it is anticipated that if this variant turns into a problem, we have to produce a new vaccine for it.”
"In 99% of those who received three doses of the PasteCovac vaccine, the antibody increased up to four times,” Mostafavi told Radio Goftogoo.
He also called the import of vaccines a defensible policy and explained; “The import of vaccines has been a good policy, so far as domestic companies have entered the project. Domestic vaccine kits should produce scientific evidence that these vaccines are also effective in booster doses. The effectiveness of the first and second dose vaccines alone doesn’t mean the effectiveness of the third dose.”
The head of the Research Center for Emerging and Re-emerging Diseases in the Pasteur Institute of Iran stated that the country's policy is to use domestic vaccines for booster doses; “The PastoCovac vaccine is licensed for use in the age group of 12-18, and is approved for those in the range of 2-12 years old; we designed the third dose from the beginning, which is licensed for use as a booster dose for all vaccines.”
Addressing the people, Mostafavi said; “Indeed it’s not a personal decision whether or not getting vaccinated, and other people in the community should be considered; besides, those who have been vaccinated should get the booster vaccine after 3 months of the second dose.”
By Farzaneh Moradi
